close 73% van de retail rekeningen verliezen gelden met de handel in CFD`s bij deze aanbieder. Investeringen zijn risicovol en zijn niet geschikt voor alle beleggers. CFD`s zijn complexe instrumenten met een hoog risico om snel gelden te verliezen vanwege het hefboomeffect. 73% van de retail beleggers lijdt verlies bij het handelen in CFD`s met deze aanbieder. Het is belangrijk dat u goed begrijpt hoe CFD`s werken en dat u nagaat of u zich het hoge risico op verlies kunt permitteren.
ZoekenZoeken
Change languageNederlands
Dashboard

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

Home・Aandelen Lijst・Karyopharm Therapeutics Inc
Search

Karyopharm Therapeutics Inc

Gesloten

SectorGezondheidszorg

9.08 8.74

Strong Buy

Prijsupdate 17 feb 2026, 20:59 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.18

Max

9.91

Belangrijke statistieken

By Trading Economics

Inkomsten

4.1M

-33M

Verkoop

6.1M

44M

EPS

-3.82

Winstmarge

-75.213

Werknemers

279

EBITDA

1.8M

-23M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+94.29% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

13M

116M

Vorige openingsprijs

0.34

Vorige sluitingsprijs

9.08

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

5.9501 / 7.66 Steun & Weerstand

Karyopharm Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 feb 2026, 23:44 UTC

Populaire aandelen

Stocks to Watch: La-Z-Boy, Palo Alto Networks, Caesars

DJ

Lezen

17 feb 2026, 23:20 UTC

Winsten

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps -- Update

DJ

Lezen

17 feb 2026, 22:57 UTC

Winsten

Santos Fiscal Year Net Profit Falls 33%, Nears Start of Alaska Project

DJ

Lezen

17 feb 2026, 21:59 UTC

Winsten

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps

DJ

Lezen

17 feb 2026, 23:54 UTC

Marktinformatie

Nikkei May Rise as Fears About AI Disruption Ease -- Market Talk

DJ

Lezen

17 feb 2026, 23:54 UTC

Marktinformatie

Global Equities Roundup: Market Talk

DJ

Lezen

17 feb 2026, 23:54 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

DJ

Lezen

17 feb 2026, 23:45 UTC

Marktinformatie

Suncorp's Outperformance of IAG Could Be Hard to Sustain -- Market Talk

DJ

Lezen

17 feb 2026, 23:19 UTC

Winsten

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

DJ

Lezen

17 feb 2026, 23:15 UTC

Winsten

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

DJ

Lezen

17 feb 2026, 22:58 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Netflix Would Operate Warner's Studios, HBO Largely the Same -- Market Talk

DJ

Lezen

17 feb 2026, 22:58 UTC

Acquisities, Fusies, Overnames

BlueScope Steel: Board Committed to Optimizing Value For Shareholders

DJ

Lezen

17 feb 2026, 22:57 UTC

Acquisities, Fusies, Overnames

BlueScope Steel to Consider Revised SGH, Steel Dynamics Takeover Bid

DJ

Lezen

17 feb 2026, 22:50 UTC

Acquisities, Fusies, Overnames

Agnico-Eagle Mines Acquired 662,780 Common Shrs of Maple Gold Mines at C$2.45 Per Common Shr >AEM.T

DJ

Lezen

17 feb 2026, 22:44 UTC

Winsten

Palo Alto Reports Strong Earnings. Its Stock Is Down. -- Barrons.com

DJ

Lezen

17 feb 2026, 22:42 UTC

Winsten

Santos FY Net Profit Falls 33%, Nears Start of Alaska Project

DJ

Lezen

17 feb 2026, 22:36 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Netflix Sarandos: Paramount Causing Confusion Around Warner Deal -- Market Talk

DJ

Lezen

17 feb 2026, 22:36 UTC

Winsten

Santos Final Dividend 10.3 U.S. Cents/Security

DJ

Lezen

17 feb 2026, 22:36 UTC

Winsten

Santos FY Underlying Profit US$898 Million, Down 25%

DJ

Lezen

17 feb 2026, 22:35 UTC

Winsten

Santos FY Revenue US$4.94 Billion, Down 8%

DJ

Lezen

17 feb 2026, 22:35 UTC

Winsten

Correct: Santos FY Net Profit US$818 Million, Down 33%

DJ

Lezen

17 feb 2026, 22:35 UTC

Acquisities, Fusies, Overnames

Berkshire Buys New York Times Stock; Sells Apple, Bank of America, Amazon In 4Q -- Barrons.com

DJ

Lezen

17 feb 2026, 22:34 UTC

Winsten

Santos FY Net Profit US$818 Billion, Down 33%

DJ

Lezen

17 feb 2026, 22:02 UTC

Acquisities, Fusies, Overnames

Berkshire Pares Stakes in Apple and BofA, Adds New York Times Position -- Update

DJ

Lezen

17 feb 2026, 21:50 UTC

Acquisities, Fusies, Overnames

Steel Dynamics: SGH Would Buy BlueScope, On-sell North American Operations to SDI, As Earlier Proposed

DJ

Lezen

17 feb 2026, 21:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

DJ

Lezen

17 feb 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

DJ

Lezen

17 feb 2026, 21:49 UTC

Acquisities, Fusies, Overnames

Steel Dynamics Says Revised Proposal Continues to Present Highly Strategic Opportunity For SDI Shareholders

DJ

Lezen

17 feb 2026, 21:48 UTC

Acquisities, Fusies, Overnames

Steel Dynamics: BlueScope Offer a 56% Premium to 52-Week Volume Weighted Average Price

DJ

Lezen

17 feb 2026, 21:48 UTC

Acquisities, Fusies, Overnames

Steel Dynamics: Consideration To Be Comprised Entirely of Cash

DJ

Lezen

Peer Vergelijking

Prijswijziging

Karyopharm Therapeutics Inc Prognose

Koersdoel

By TipRanks

94.29% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 16.67 USD  94.29%

Hoogste 23 USD

Laagste 12 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Karyopharm Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Karyopharm Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

5.9501 / 7.66Steun & Weerstand

Korte Termijn

Bullish Evidence

Recent bullish events outweigh bearish events.

Gemiddeld Termijn

Strong Bearish Evidence

All events are bearish.

Lange Termijn

No Evidence

There are no events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Andere aandelen uit de sector

LLY

Eli Lilly and Co.

1,036.37

↓-0.35%

JNJ

Johnson and Johnson

243.49

↑ +0.08%

ABBV

AbbVie Inc

232.69

↑ +0.55%

NVS

Novartis AG

166.17

↑ +2.06%

MRK

Merck & Co Inc.

121.6

↑ +0.22%
help-icon Live chat